Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 31,167 shares, a decrease of 53.9% from the October 15th total of 67,594 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 70,312 shares, the short-interest ratio is currently 0.4 days.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Zhengye Biotechnology in a report on Friday, October 16th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
Check Out Our Latest Research Report on ZYBT
Zhengye Biotechnology Stock Performance
Shares of NASDAQ:ZYBT remained flat at $1.50 during midday trading on Friday. 21,323 shares of the stock traded hands, compared to its average volume of 50,129. Zhengye Biotechnology has a 12-month low of $0.62 and a 12-month high of $8.01. The business’s 50-day moving average is $1.41 and its 200 day moving average is $1.18.
Zhengye Biotechnology (NASDAQ:ZYBT – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter. The business had revenue of $3.75 million for the quarter.
Zhengye Biotechnology Company Profile
Zhengye Biotechnology is a China-based veterinary biotechnology company that develops, manufactures and sells vaccines and related products for animal health. Its offerings include vaccines used to help prevent infectious diseases in livestock and poultry. The company serves customers in China’s animal agriculture sector, including producers and veterinary businesses. Its operating history dates to 2004, when its principal operating business was established. Zhengye also conducts research and development and provides technical support related to its products.
Featured Stories
- Five stocks we like better than Zhengye Biotechnology
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Zhengye Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhengye Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
